You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesvenlafaxine
Accession NumberDB06700
TypeSmall Molecule
GroupsApproved
DescriptionDesvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.
Structure
Thumb
Synonyms
Desvenlafaxine
O-desmethylvenlafaxine
ODV
Pristiq
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesvenlafaxineTablet, extended release50 mg/1OralSun Pharma Global FZE2014-01-30Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1OralSun Pharma Global FZE2014-01-30Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1OralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
Desvenlafaxine Extended-releaseTablet, extended release100 mg/1OralMacoven Pharmaceuticals2013-07-10Not applicableUs
Desvenlafaxine Extended-releaseTablet, extended release50 mg/1OralMacoven Pharmaceuticals2013-07-10Not applicableUs
Khedezla Extended-releaseTablet, extended release50 mg/1OralPar Pharmaceutical Inc.2013-07-102016-10-29Us
Khedezla Extended-releaseTablet, extended release100 mg/1OralPar Pharmaceutical Inc.2013-07-102016-10-29Us
Khedezla Extended-releaseTablet, extended release50 mg/1OralPernix Therapeutics2013-07-10Not applicableUs
Khedezla Extended-releaseTablet, extended release100 mg/1OralPernix Therapeutics2013-07-10Not applicableUs
PristiqTablet, extended release50 mgOralPfizer Canada Inc2009-03-05Not applicableCanada
PristiqTablet, extended release100 mgOralPfizer Canada Inc2009-03-06Not applicableCanada
Pristiq Extended ReleaseTablet, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-26Not applicableUs
Pristiq Extended-releaseTablet, extended release25 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2015-04-01Not applicableUs
Pristiq Extended-releaseTablet, extended release50 mg/1OralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releaseTablet, extended release50 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-releaseTablet, extended release100 mg/1OralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releaseTablet, extended release100 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-releaseTablet, extended release50 mg/1OralPhysicians Total Care, Inc.2008-05-01Not applicableUs
Pristiq Extended-releaseTablet, extended release50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Pristiq Extended-release Extended-releaseTablet, extended release50 mg/1OralPd Rx Pharmaceuticals, Inc.2008-05-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesvenlafaxineTablet, extended release50 mg/1OralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1OralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Zyven-OD Not Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desvenlafaxine fumarate
93414-04-1
Thumb
  • InChI Key: SQTJDJZCPOSWSC-WLHGVMLRSA-N
  • Monoisotopic Mass: 379.199487658
  • Average Mass: 379.453
DBSALT001322
Desvenlafaxine fumarate monohydrate
313471-75-9
Thumb
  • InChI Key: YETWCSLOYUZBLK-JITBQSAISA-N
  • Monoisotopic Mass: 397.210052342
  • Average Mass: 397.468
DBSALT001893
Desvenlafaxine succinate
Thumb
  • InChI Key: ORUUBRMVQCKYHB-UHFFFAOYNA-N
  • Monoisotopic Mass: 381.215137729
  • Average Mass: 381.4632
DBSALT000045
Categories
UNIING99554ANW
CAS number93413-62-8
WeightAverage: 263.3752
Monoisotopic: 263.188529049
Chemical FormulaC16H25NO2
InChI KeyKYYIDSXMWOZKMP-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
IUPAC Name
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Pharmacology
IndicationDesvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Structured Indications
PharmacodynamicsDesvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose. Some of the limitations of desvenlafaxine include moderate efficacy in the treatment of major depressive disorder, similar safety and tolerability profile to other SNRIs and possible transient discontinuation symptoms upon cessation of therapy.
Mechanism of actionDesvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Related Articles
AbsorptionAbsolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.
Volume of distribution

3.4 L/kg, distribution into nonvascular compartments

Protein binding~ 30%, protein binding is independent of drug concentration.
Metabolism

The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.

SubstrateEnzymesProduct
Desvenlafaxine
N,O-DidesmethylvenlafaxineDetails
Route of eliminationExcreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.
Half lifeThe mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.
ClearanceNot Available
ToxicityThe safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Venlafaxine Metabolism PathwayDrug metabolismSMP00636
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Desvenlafaxine.Investigational
4-MethoxyamphetamineDesvenlafaxine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desvenlafaxine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Desvenlafaxine.Experimental
AcarboseDesvenlafaxine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acetophenazine.Approved
Acetylsalicylic acidDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Desvenlafaxine.Investigational
AdrafinilDesvenlafaxine may increase the tachycardic activities of Adrafinil.Withdrawn
AgmatineDesvenlafaxine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desvenlafaxine.Approved, Investigational
AlbiglutideDesvenlafaxine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desvenlafaxine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desvenlafaxine.Approved, Investigational
AlogliptinDesvenlafaxine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desvenlafaxine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Desvenlafaxine.Approved, Withdrawn
AmiodaroneThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.Approved, Investigational
AmitrazDesvenlafaxine may increase the tachycardic activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desvenlafaxine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desvenlafaxine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desvenlafaxine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amperozide.Experimental
AnisodamineDesvenlafaxine may increase the tachycardic activities of Anisodamine.Investigational
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Desvenlafaxine.Investigational
ApomorphineDesvenlafaxine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDesvenlafaxine may increase the tachycardic activities of Apraclonidine.Approved
AprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineDesvenlafaxine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolDesvenlafaxine may increase the tachycardic activities of Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desvenlafaxine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Asenapine.Approved
AtazanavirThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desvenlafaxine.Approved
AtomoxetineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Azaperone.Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desvenlafaxine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desvenlafaxine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.Illicit
BefunololDesvenlafaxine may increase the tachycardic activities of Befunolol.Experimental
BendroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Desvenlafaxine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desvenlafaxine.Approved
BenzphetamineDesvenlafaxine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desvenlafaxine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine.Approved
BethanidineDesvenlafaxine may decrease the antihypertensive activities of Bethanidine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved
BexaroteneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Bifeprunox.Investigational
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Desvenlafaxine.Approved
BitolterolDesvenlafaxine may increase the tachycardic activities of Bitolterol.Withdrawn
BoceprevirThe metabolism of Desvenlafaxine can be decreased when combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Desvenlafaxine.Approved
BortezomibThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brexpiprazole.Approved
BrimonidineDesvenlafaxine may increase the tachycardic activities of Brimonidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desvenlafaxine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desvenlafaxine.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Desvenlafaxine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desvenlafaxine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desvenlafaxine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desvenlafaxine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desvenlafaxine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desvenlafaxine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desvenlafaxine.Approved
CanagliflozinDesvenlafaxine may increase the hypoglycemic activities of Canagliflozin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Desvenlafaxine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desvenlafaxine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Desvenlafaxine.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desvenlafaxine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Desvenlafaxine.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Desvenlafaxine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CelecoxibDesvenlafaxine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CeritinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desvenlafaxine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desvenlafaxine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desvenlafaxine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desvenlafaxine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desvenlafaxine.Approved
ChlorothiazideDesvenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideDesvenlafaxine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneDesvenlafaxine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desvenlafaxine.Approved
CimetidineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desvenlafaxine.Approved, Vet Approved
CirazolineDesvenlafaxine may increase the tachycardic activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.Approved
ClarithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Desvenlafaxine can be decreased when combined with Clemastine.Approved
ClenbuterolDesvenlafaxine may increase the tachycardic activities of Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desvenlafaxine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Desvenlafaxine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desvenlafaxine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desvenlafaxine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desvenlafaxine.Approved, Illicit
ClonidineDesvenlafaxine may increase the tachycardic activities of Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desvenlafaxine.Approved, Illicit
ClotrimazoleThe metabolism of Desvenlafaxine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Desvenlafaxine.Approved
CobicistatThe metabolism of Desvenlafaxine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desvenlafaxine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
ConivaptanThe serum concentration of Desvenlafaxine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Desvenlafaxine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Desvenlafaxine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved
CyclosporineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Desvenlafaxine.Approved
DapagliflozinDesvenlafaxine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.Investigational
DarunavirThe metabolism of Desvenlafaxine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Desvenlafaxine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Desvenlafaxine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desvenlafaxine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desvenlafaxine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.Approved
DetomidineDesvenlafaxine may increase the tachycardic activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine.Approved
DexmedetomidineDesvenlafaxine may increase the tachycardic activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanDesvenlafaxine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Desvenlafaxine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desvenlafaxine.Approved, Illicit, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Desvenlafaxine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desvenlafaxine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DiltiazemThe metabolism of Desvenlafaxine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desvenlafaxine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desvenlafaxine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DipivefrinDesvenlafaxine may increase the tachycardic activities of Dipivefrin.Approved
DisopyramideDesvenlafaxine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineDesvenlafaxine may increase the tachycardic activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Desvenlafaxine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desvenlafaxine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Desvenlafaxine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.Approved
DoxycyclineThe metabolism of Desvenlafaxine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Desvenlafaxine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Desvenlafaxine.Investigational
DronedaroneThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desvenlafaxine.Experimental, Illicit
DroxidopaDesvenlafaxine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DulaglutideDesvenlafaxine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desvenlafaxine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Desvenlafaxine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Desvenlafaxine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desvenlafaxine.Approved, Investigational
EmpagliflozinDesvenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desvenlafaxine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desvenlafaxine.Approved, Investigational
EnzalutamideThe serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.Approved
EphedraDesvenlafaxine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDesvenlafaxine may increase the tachycardic activities of Ephedrine.Approved
EpinephrineDesvenlafaxine may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desvenlafaxine.Approved
ErythromycinThe metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desvenlafaxine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Desvenlafaxine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desvenlafaxine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desvenlafaxine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desvenlafaxine.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desvenlafaxine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desvenlafaxine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desvenlafaxine.Withdrawn
EtilefrineDesvenlafaxine may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desvenlafaxine.Approved
EtodolacDesvenlafaxine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateDesvenlafaxine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneDesvenlafaxine may increase the serotonergic activities of Etoperidone.Approved
EtoricoxibDesvenlafaxine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Desvenlafaxine.Illicit, Vet Approved
EtravirineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Etravirine.Approved
ExenatideDesvenlafaxine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Desvenlafaxine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desvenlafaxine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineDesvenlafaxine may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FenoterolDesvenlafaxine may increase the tachycardic activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desvenlafaxine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Desvenlafaxine.Approved
FluconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.Approved, Illicit
FluindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Desvenlafaxine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desvenlafaxine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desvenlafaxine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desvenlafaxine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desvenlafaxine.Approved, Investigational
FormoterolDesvenlafaxine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Desvenlafaxine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Desvenlafaxine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desvenlafaxine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Desvenlafaxine.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Desvenlafaxine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Desvenlafaxine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Desvenlafaxine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Desvenlafaxine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desvenlafaxine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Desvenlafaxine.Investigational
GliclazideDesvenlafaxine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDesvenlafaxine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDesvenlafaxine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desvenlafaxine.Approved, Illicit
GlyburideDesvenlafaxine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
GuanabenzDesvenlafaxine may increase the tachycardic activities of Guanabenz.Approved
GuanfacineDesvenlafaxine may increase the tachycardic activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desvenlafaxine.Approved
HexoprenalineDesvenlafaxine may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HigenamineDesvenlafaxine may increase the tachycardic activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Desvenlafaxine.Approved
HydrochlorothiazideDesvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.Approved, Illicit
HydroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Desvenlafaxine.Approved
IdelalisibThe serum concentration of Desvenlafaxine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.Approved
ImatinibThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.Approved
IndalpineDesvenlafaxine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideDesvenlafaxine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Desvenlafaxine.Withdrawn
IndinavirThe metabolism of Desvenlafaxine can be decreased when combined with Indinavir.Approved
Insulin AspartDesvenlafaxine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDesvenlafaxine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDesvenlafaxine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDesvenlafaxine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDesvenlafaxine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDesvenlafaxine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desvenlafaxine.Approved
Ioflupane I-123Desvenlafaxine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Desvenlafaxine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Desvenlafaxine.Withdrawn
IsavuconazoniumThe metabolism of Desvenlafaxine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Desvenlafaxine.Approved
IsoetarineDesvenlafaxine may increase the tachycardic activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desvenlafaxine.Approved, Vet Approved
IsoprenalineDesvenlafaxine may increase the tachycardic activities of Isoprenaline.Approved
IsoxsuprineDesvenlafaxine may increase the tachycardic activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Desvenlafaxine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desvenlafaxine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desvenlafaxine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Desvenlafaxine.Approved
KetoconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Desvenlafaxine.Approved, Nutraceutical
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desvenlafaxine.Approved, Investigational
LanreotideDesvenlafaxine may increase the hypoglycemic activities of Lanreotide.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desvenlafaxine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Desvenlafaxine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desvenlafaxine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Desvenlafaxine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Desvenlafaxine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Desvenlafaxine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Desvenlafaxine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Desvenlafaxine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Desvenlafaxine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Desvenlafaxine.Approved
LiraglutideDesvenlafaxine may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Desvenlafaxine.Approved
LofentanilLofentanil may increase the serotonergic activities of Desvenlafaxine.Illicit
LofexidineDesvenlafaxine may increase the tachycardic activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desvenlafaxine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desvenlafaxine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Desvenlafaxine.Approved
LovastatinThe metabolism of Desvenlafaxine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Loxapine.Approved
Lu AA21004Desvenlafaxine may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Desvenlafaxine can be increased when combined with Lumacaftor.Approved
LumiracoxibDesvenlafaxine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Desvenlafaxine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.Approved
MebanazineMebanazine may increase the serotonergic activities of Desvenlafaxine.Withdrawn
MecaserminDesvenlafaxine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desvenlafaxine.Approved
MedetomidineDesvenlafaxine may increase the tachycardic activities of Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desvenlafaxine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Melperone.Approved
MephentermineDesvenlafaxine may increase the tachycardic activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desvenlafaxine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.Approved
MetaraminolDesvenlafaxine may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desvenlafaxine.Approved
MetforminDesvenlafaxine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Desvenlafaxine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
MethamphetamineDesvenlafaxine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desvenlafaxine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desvenlafaxine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desvenlafaxine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desvenlafaxine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Methotrimeprazine.Approved
MethoxamineDesvenlafaxine may increase the tachycardic activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desvenlafaxine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.Approved
MethyclothiazideDesvenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
MethyldopaDesvenlafaxine may increase the tachycardic activities of Methyldopa.Approved
Methylene blueDesvenlafaxine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desvenlafaxine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Desvenlafaxine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.Approved, Investigational
MetolazoneDesvenlafaxine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Desvenlafaxine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.Approved, Illicit
MidodrineDesvenlafaxine may increase the tachycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Desvenlafaxine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolDesvenlafaxine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desvenlafaxine.Approved
MinaprineMinaprine may increase the serotonergic activities of Desvenlafaxine.Approved
MirabegronDesvenlafaxine may increase the tachycardic activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desvenlafaxine.Approved
MitotaneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Desvenlafaxine.Approved
ModafinilThe serum concentration of Desvenlafaxine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Molindone.Approved
MorphineMorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Desvenlafaxine.Approved, Investigational
NabumetoneDesvenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.Approved
NafcillinThe serum concentration of Desvenlafaxine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Desvenlafaxine.Approved
NaphazolineDesvenlafaxine may increase the tachycardic activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Desvenlafaxine.Approved, Investigational
NateglinideDesvenlafaxine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololDesvenlafaxine may increase the tachycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Desvenlafaxine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Desvenlafaxine.Withdrawn
NilotinibThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Desvenlafaxine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desvenlafaxine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desvenlafaxine.Approved, Vet Approved
NorepinephrineDesvenlafaxine may increase the tachycardic activities of Norepinephrine.Approved
NormethadoneNormethadone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desvenlafaxine.Approved
NylidrinDesvenlafaxine may increase the tachycardic activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Desvenlafaxine.Withdrawn
OctreotideDesvenlafaxine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineDesvenlafaxine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.Approved
OlodaterolDesvenlafaxine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desvenlafaxine.Approved
OndansetronOndansetron may increase the serotonergic activities of Desvenlafaxine.Approved
OpiumOpium may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
OrciprenalineDesvenlafaxine may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desvenlafaxine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Desvenlafaxine.Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Desvenlafaxine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desvenlafaxine.Approved
OxycodoneOxycodone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational
OxymetazolineDesvenlafaxine may increase the tachycardic activities of Oxymetazoline.Approved
OxymorphoneOxymorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.Approved
PaliperidoneDesvenlafaxine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desvenlafaxine.Approved
ParecoxibDesvenlafaxine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Desvenlafaxine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.Approved, Investigational
PasireotideDesvenlafaxine may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
PentamidineDesvenlafaxine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Desvenlafaxine.Approved, Vet Approved
PentobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Desvenlafaxine.Approved
PerazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perazine.Investigational
PergolideDesvenlafaxine may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desvenlafaxine.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Desvenlafaxine.Approved
PhenindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Desvenlafaxine.Withdrawn
PhenobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desvenlafaxine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Desvenlafaxine.Withdrawn
PhenprocoumonThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenprocoumon.Approved
PhenylephrineDesvenlafaxine may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineDesvenlafaxine may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Desvenlafaxine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Desvenlafaxine.Approved
PioglitazoneDesvenlafaxine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipotiazine.Approved
PirbuterolDesvenlafaxine may increase the tachycardic activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Desvenlafaxine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Desvenlafaxine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Desvenlafaxine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Desvenlafaxine.Approved
PolythiazideDesvenlafaxine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desvenlafaxine.Approved
PosaconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Desvenlafaxine.Approved
PramlintideDesvenlafaxine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desvenlafaxine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desvenlafaxine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Desvenlafaxine.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desvenlafaxine.Approved
PrimidoneThe metabolism of Desvenlafaxine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Desvenlafaxine.Approved
ProcaterolDesvenlafaxine may increase the tachycardic activities of Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desvenlafaxine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desvenlafaxine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desvenlafaxine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desvenlafaxine.Investigational
PseudoephedrineDesvenlafaxine may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desvenlafaxine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.Approved
QuinethazoneDesvenlafaxine may increase the hyponatremic activities of Quinethazone.Approved
QuinineDesvenlafaxine may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineDesvenlafaxine may increase the tachycardic activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Raclopride.Investigational
RactopamineDesvenlafaxine may increase the tachycardic activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine.Approved, Investigational
RanolazineThe metabolism of Desvenlafaxine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Desvenlafaxine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Desvenlafaxine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.Approved, Withdrawn
RepaglinideDesvenlafaxine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.Approved
RifabutinThe metabolism of Desvenlafaxine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Desvenlafaxine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Desvenlafaxine can be increased when combined with Rifapentine.Approved
RilmenidineDesvenlafaxine may increase the tachycardic activities of Rilmenidine.Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Desvenlafaxine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ritanserin.Investigational
RitobegronDesvenlafaxine may increase the tachycardic activities of Ritobegron.Investigational
RitodrineDesvenlafaxine may increase the tachycardic activities of Ritodrine.Approved
RitonavirThe metabolism of Desvenlafaxine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Desvenlafaxine.Approved
RofecoxibDesvenlafaxine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineDesvenlafaxine may increase the tachycardic activities of Romifidine.Vet Approved
RopiniroleDesvenlafaxine may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine.Approved
RosiglitazoneDesvenlafaxine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desvenlafaxine.Experimental
SafrazineSafrazine may increase the serotonergic activities of Desvenlafaxine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Desvenlafaxine.Investigational
SalbutamolDesvenlafaxine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolDesvenlafaxine may increase the tachycardic activities of Salmeterol.Approved
SaquinavirThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinDesvenlafaxine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desvenlafaxine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desvenlafaxine.Approved, Vet Approved
SildenafilThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Desvenlafaxine can be increased when it is combined with Simeprevir.Approved
SitagliptinDesvenlafaxine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Desvenlafaxine.Approved
SolabegronDesvenlafaxine may increase the tachycardic activities of Solabegron.Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Desvenlafaxine.Approved
SR 58611Desvenlafaxine may increase the tachycardic activities of SR 58611.Investigational
St. John's WortThe serum concentration of Desvenlafaxine can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Desvenlafaxine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
SulfadiazineDesvenlafaxine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleDesvenlafaxine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Desvenlafaxine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Desvenlafaxine.Approved, Investigational
SunitinibDesvenlafaxine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Desvenlafaxine.Approved
SynephrineDesvenlafaxine may increase the tachycardic activities of Synephrine.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Desvenlafaxine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desvenlafaxine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Desvenlafaxine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desvenlafaxine.Approved
TelaprevirThe metabolism of Desvenlafaxine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desvenlafaxine.Approved
TerbutalineDesvenlafaxine may increase the tachycardic activities of Terbutaline.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Desvenlafaxine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desvenlafaxine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desvenlafaxine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desvenlafaxine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desvenlafaxine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Desvenlafaxine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desvenlafaxine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Desvenlafaxine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desvenlafaxine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Desvenlafaxine.Approved
TizanidineDesvenlafaxine may increase the tachycardic activities of Tizanidine.Approved
TocilizumabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.Approved
TolazamideDesvenlafaxine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideDesvenlafaxine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desvenlafaxine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Desvenlafaxine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Desvenlafaxine.Approved
TramadolDesvenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Desvenlafaxine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desvenlafaxine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desvenlafaxine.Approved
TrichlormethiazideDesvenlafaxine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desvenlafaxine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desvenlafaxine.Approved
TropisetronTropisetron may increase the serotonergic activities of Desvenlafaxine.Investigational
TulobuterolDesvenlafaxine may increase the tachycardic activities of Tulobuterol.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Desvenlafaxine.Investigational
ValdecoxibDesvenlafaxine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desvenlafaxine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Desvenlafaxine.Approved
VerapamilThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Desvenlafaxine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desvenlafaxine.Approved
VoriconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Vortioxetine.Approved
WarfarinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.Approved
XylazineDesvenlafaxine may increase the tachycardic activities of Xylazine.Vet Approved
XylometazolineDesvenlafaxine may decrease the antihypertensive activities of Xylometazoline.Approved
YM-178Desvenlafaxine may increase the tachycardic activities of YM-178.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Desvenlafaxine.Approved
ZimelidineDesvenlafaxine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desvenlafaxine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desvenlafaxine.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desvenlafaxine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desvenlafaxine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desvenlafaxine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Karel Pospisilik, Lambertus Thijs, “Process for making desvenlafaxine.” U.S. Patent US20070299283, issued December 27, 2007.

US20070299283
General References
  1. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994 ]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  3. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382 ]
  4. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  5. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  6. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354 ]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022 ]
  8. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490 ]
  9. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
  10. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
  11. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106 ]
  12. Link [Link]
External Links
ATC CodesN06AX23
AHFS Codes
  • 28:16.04.16
PDB EntriesNot Available
FDA labelDownload (379 KB)
MSDSDownload (86.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.7722
Caco-2 permeable+0.8404
P-glycoprotein substrateSubstrate0.6918
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IIInhibitor0.5921
Renal organic cation transporterNon-inhibitor0.5894
CYP450 2C9 substrateNon-substrate0.7837
CYP450 2D6 substrateSubstrate0.7753
CYP450 3A4 substrateSubstrate0.6997
CYP450 1A2 substrateNon-inhibitor0.6816
CYP450 2C9 inhibitorNon-inhibitor0.757
CYP450 2D6 inhibitorInhibitor0.6334
CYP450 2C19 inhibitorNon-inhibitor0.7811
CYP450 3A4 inhibitorNon-inhibitor0.8646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8888
Ames testNon AMES toxic0.8084
CarcinogenicityNon-carcinogens0.7648
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4429 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6046
hERG inhibition (predictor II)Inhibitor0.5603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral50 mg
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Pristiq 100 mg extended-release tablet4.46USD tablet
Pristiq 50 mg extended-release tablet4.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2436668 No2009-05-262022-02-11Canada
US6673838 No2002-03-012022-03-01Us
US8269040 No2007-07-052027-07-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble FDA label
logP0.21FDA label
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP2.6ALOGPS
logP2.29ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m3·mol-1ChemAxon
Polarizability30.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:22 / Updated on December 03, 2016 02:44